Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

March 2, 2015
Otsuka Pharmaceutical

Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
March 2, 2015
Taiho Pharmaceutical

Taiho Submits TAS-102 (brand name in Japan: "Lonsurf®") Marketing Authorization Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer
February 27, 2015
Otsuka Pharmaceutical

CHMP Recommends JINARC® (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
February 27, 2015
Otsuka Pharmaceutical

First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease
February 27, 2015
Otsuka Holdings

Otsuka Pharmaceutical Receives Princess Chichibu Memorial Award for Distinguished Service to Tuberculosis Elimination
February 26, 2015
Otsuka Pharmaceutical

TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
February 26, 2015
Otsuka Holdings

TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
February 23, 2015
Taiho Pharmaceutical

Taiho Pharmaceutical Announces TAS-102 (brand name in Japan: "Lonsurf®") New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
February 20, 2015
Otsuka Pharmaceutical

Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures
February 20, 2015
Otsuka Pharmaceutical

New UL・OS Facial and Body Wipes
February 18, 2015
Otsuka Pharmaceutical

Supporting Tokyo Marathon Runners with Beverages and Nutrition Before, During, and After the Race
February 13, 2015
Otsuka Holdings

Otsuka Holdings Announces Personnel Change of Representative Director
February 12, 2015
Otsuka Holdings

Notice of Change of Representative Director of Otsuka Pharmaceutical Co Ltd (Concurrent Obituary）
February 2, 2015
Otsuka Pharmaceutical

Otsuka Pharmaceutical Expands Overseas Distribution of ORONAMIN C DRINK Carbonated nutritional beverage to be produced and sold in South Korea
January 28, 2015
Otsuka Holdings

Otsuka announces 2014 fourth quarter U.S. net sales figures of ABILIFY®
January 27, 2015
Otsuka Pharmaceutical

Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia
January 13, 2015
Otsuka Holdings

Otsuka Pharmaceutical Completes Acquisition of Avanir Pharmaceuticals
January 8, 2015
Otsuka Pharmaceutical

Terminations of Otsuka's Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine for Pancreatic Cancer and Otsuka's Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102
January 8, 2015
Otsuka Holdings

Terminations of Otsuka’s Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine For Pancreatic Cancer and Otsuka’s Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102
January 5, 2015
Taiho Pharmaceutical

Taiho Pharmaceutical Receives Approval to Manufacture and Market ZOSYN® 4.5 for I.V. Infusion Bag, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
January 5, 2015
Otsuka Holdings

Otsuka Holdings Announces Expiration of HSR Waiting Period for Avanir Tender Offer